Medplus Health Services Limited (MEDPLUS) Fair Value & Analysis
Healthcare · IN · Market cap ₹98.1B (≈ $1.0B) · ISIN INE804L01022
What is Medplus Health Services Limited really worth?
A solid business, currently priced close to our fair value of ₹682.65.
Strengths
Risks
Fair value as of: Aug 27, 2026
From 24 valuation models · updated 9 days ago
Fair value updated Aug 27, 2026, revised from ₹379.25 to ₹682.65 (+80.0%) since Aug 13, 2026. Share price −2.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (₹475.94 to ₹864.25) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
56‑month range ₹576.30 – ₹1,290 · fair‑value band ₹475.94 – ₹864.25 · the ₹676.35 price screens below the ₹682.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Medplus Health Services Limited (MEDPLUS) currently trades at ₹676.35, while our model-based Fair Value estimate is ₹682.65, implying the stock looks roughly 0.9% fairly valued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ₹661.21 per share, and 7 of the 24 models we run sit above the ₹676.35 price. Bear case: the Asset-Based group reads lowest at ₹110.21, and 17 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Medplus Health Services Limited generated revenue of ₹68.9B at a net margin of 3.2%. Revenue grew 23.5% year over year. It earns a return on equity of 11.8%. Net debt stands at ₹9.6B. Fundamentals as of Aug 27, 2026
Our scenario range runs from ₹475.94 (bear case) to ₹864.25 (bull case); at ₹676.35, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 1%, MEDPLUS screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹7.87 per share, which is 1.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (₹661.21) versus Asset-Based (₹110.21). Highest evidence: FCF DCF (76).
Notify me when MEDPLUS reaches fair value
Put MEDPLUS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care …
Full company description
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Medplus Health Services Limited reported revenue of ₹68.9B in FY2026 versus ₹37.8B in FY2022, a compound +16.2%/yr. Reported net income was ₹2.2B in FY2026, compounding +23.1%/yr from FY2022.
Watch MEDPLUS: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
| Luyan Pharma Co 002788 | ¥10.96 | ¥15.91 | +45% |
Compare Medplus Health Services Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medplus Health Services Limited (MEDPLUS) overvalued or undervalued?
What is the fair value of MEDPLUS?
What is the quality score of MEDPLUS?
What is the revenue of Medplus Health Services Limited (MEDPLUS)?
What is the net profit margin of MEDPLUS?
Watch Medplus Health Services Limited in the live analysis
One click puts Medplus Health Services Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.